Who are Levagen+'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Bacterial Lysates, Imiquimod and Interferon alpha, beta-1,3-glucan, OM-85 BV (Broncho-Vaxom), Poly IC, diphenylcyclopropenone (DPCP).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/levagen.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Levagen+ — Competitive Intelligence Brief

Levagen+ (Levagen+) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Immunostimulant. Area: Dermatology / Wound Care.

marketed Immunostimulant Immune cell activation (non-specific) Dermatology / Wound Care Small molecule Live · refreshed every 30 min

Target snapshot

Levagen+ (Levagen+) — RDC Clinical Pty Ltd. Levagen+ is a topical formulation containing levamisole that enhances immune function and promotes wound healing through immunomodulatory mechanisms.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Levagen+ TARGET	Levagen+	RDC Clinical Pty Ltd	marketed	Immunostimulant	Immune cell activation (non-specific)
Bacterial Lysates	Bacterial Lysates	Sanofi	marketed	Immunostimulant; bacterial lysate
Imiquimod and Interferon alpha	Imiquimod and Interferon alpha	The University of Texas Health Science Center, Houston	marketed	Immunostimulant combination	TLR7/8 (imiquimod); Interferon-alpha receptor (interferon alpha)
beta-1,3-glucan	beta-1,3-glucan	Meiji University of Oriental Medicine	marketed	Immunostimulant / Biological response modifier	Dectin-1 (and other pattern recognition receptors)
OM-85 BV (Broncho-Vaxom)	OM-85 BV (Broncho-Vaxom)	Kecioren Education and Training Hospital	marketed	Bacterial lysate immunostimulant
Poly IC	Poly IC	Union Hospital, Tongji Medical College, Huazhong University of Science and Technology	marketed	TLR3 agonist / Immunostimulant	TLR3 (Toll-like receptor 3)
diphenylcyclopropenone (DPCP)	diphenylcyclopropenone (DPCP)	Ain Shams University	marketed	Contact sensitizer / Immunostimulant

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Immunostimulant class)

Assistance Publique - Hôpitaux de Paris · 1 drug in this class
Biotec Pharmacon ASA · 1 drug in this class
RDC Clinical Pty Ltd · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Levagen+ — Competitive Intelligence Brief. https://druglandscape.com/ci/levagen. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab